BEAM - Gene editing stocks buoyed in afternoon trading by Intellia CRISPR success

ipopba/iStock via Getty Images Several gene editing stocks are flying high in afternoon trading, the beneficiaries of news from over the weekend on Intellia Therapeutics' (NTLA) gene editing candidate NTLA-2001. Besides Intellia, which is currently up 50% in afternoon trading, Beam Therapeutics (BEAM) is the best performing of the bunch, up more than 15%. Beam's platform is focused on base editing, which the company says can "precisely and permanently rewrite a single letter of the genome and potentially create life-long cures for patients suffering from serious diseases." Its lead candidate, BEAM101, is in IND enabling stage for sickle cell disease and ?-thalassemia. CRISPR Therapeutics (CRSP) is up 7%. The company has four candidates in the clinic: CTX001, CTX110, CTX120, and CTX130. Earlier this month, CRISPR and partner Vertex released data on CTX001, which is in development for sickle cell disease and ?-thalassemia. Editas (EDIT) is up 6%. The company's most advanced asset is EDIT-101 in

For further details see:

Gene editing stocks buoyed in afternoon trading by Intellia CRISPR success